trebananib + sunitinib

Trebananib + sunitinib is a **combination therapy** studied primarily in metastatic renal cell carcinoma. **Trebananib** (AMG 386) is an investigational recombinant peptide-Fc fusion protein (peptibody) that blocks the interaction between angiopoietin-1/2 and the Tie2 receptor, thereby inhibiting angiogenesis[1][2][3]. **Sunitinib** is an oral, small molecule tyrosine kinase inhibitor that targets multiple receptor tyrosine kinases, including vascular endothelial growth factor (VEGF) receptors, platelet-derived growth factor (PDGF) receptors, and others, resulting in inhibition of tumor growth and angiogenesis[1][2][3]. The combination was investigated for potential synergistic anti-angiogenic and antitumor activity, with phase I and II studies indicating efficacy but increased toxicity compared to sunitinib alone[1][2][3][4].

Other names

trebananibsunitinib malate